Literature DB >> 30614793

Frameshift mutation of candidate tumor suppressor genes QK1 and TMEFF2 in gastric and colorectal cancers.

Ha Yoon Mo1, Yun Sol Jo1, Nam Jin Yoo1, Min Sung Kim1, Sang Yong Song2, Sug Hyung Lee1.   

Abstract

BACKGROUND: Both QKI and TMEFF2 genes are considered putative tumor suppressor genes (TSGs). In gastric (GC) and colorectal (CRC) cancers, downregulation of their expressions is known to be frequent. However, QKI and TMEFF2 mutations that could potentially inactivate their functions are not reported in cancers.
METHODS: In a genome database, we observed that both QKI and TMEFF2 harbor mononucleotide repeats, which could be mutated in cancers with high microsatellite instability (MSI-H). For this, we studied 79 GCs and 124 CRCs for the mutations and their intratumoral heterogeneity (ITH).
RESULTS: Six of 34 GCs (17.6%) and 10 of 79 CRCs (12.7%) with MSI-H exhibited QKI frameshift mutations while five of 79 CRCs (6.3%) with high MSI (MSI-H) exhibited TMEFF2 frameshift mutations. However, we found no such mutation in microsatellite stable/low MSI (MSS/MSI-L) cancers within the mononucleotide repeats. We also studied ITH for the detected frameshift mutations in 16 cases of CRCs and detected that QKI and TMEFF2 frameshift mutations showed regional ITH in 2 (12.5%) and 1 (6.3%) cases, respectively.
CONCLUSIONS: Our data show that candidate TSG genes QKI and TMEFF2 harbor mutational ITH as well as the frameshift mutations in GC and CRC with MSI-H. From this observation, frameshift mutations of QKI and TMEFF2 may play a role in tumorigenesis through their TSG inactivation in GC and CRC.

Entities:  

Keywords:  QK1; TMEFF2; cancer; frameshift mutation; methylation; microsatellite instability; tumor suppressor gene

Mesh:

Substances:

Year:  2019        PMID: 30614793     DOI: 10.3233/CBM-160559

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  4 in total

1.  Genome-wide DNA methylation differences according to oestrogen receptor beta status in colorectal cancer.

Authors:  Sonja Neumeyer; Odilia Popanda; Dominic Edelmann; Katja Butterbach; Csaba Toth; Wilfried Roth; Hendrik Bläker; Ruijingfang Jiang; Esther Herpel; Cornelia Jäkel; Peter Schmezer; Lina Jansen; Elizabeth Alwers; Axel Benner; Barbara Burwinkel; Michael Hoffmeister; Hermann Brenner; Jenny Chang-Claude
Journal:  Epigenetics       Date:  2019-03-30       Impact factor: 4.528

2.  Differential processing and localization of human Nocturnin controls metabolism of mRNA and nicotinamide adenine dinucleotide cofactors.

Authors:  Elizabeth T Abshire; Kelsey L Hughes; Rucheng Diao; Sarah Pearce; Shreekara Gopalakrishna; Raymond C Trievel; Joanna Rorbach; Peter L Freddolino; Aaron C Goldstrohm
Journal:  J Biol Chem       Date:  2020-08-23       Impact factor: 5.157

3.  PCBP1 inhibits the expression of oncogenic STAT3 isoform by targeting alternative splicing of STAT3 exon 23.

Authors:  Xiaole Wang; Jihua Guo; Xiaoxuan Che; Rong Jia
Journal:  Int J Biol Sci       Date:  2019-05-07       Impact factor: 6.580

4.  Prognostic significance of survival-associated alternative splicing events in gastric cancer.

Authors:  Shichao Zhang; Zuquan Hu; Yingwu Lan; Jinhua Long; Yun Wang; Xiaowen Chen; Xiaofeng Xu; Zhu Zeng; Yan Ouyang
Journal:  Aging (Albany NY)       Date:  2020-11-07       Impact factor: 5.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.